Corporate Inversions Showing No Signs of Slowing Down

by Bilzin Sumberg

In a corporate inversion, a U.S. corporation (typically the parent of an affiliated group) becomes a wholly owned subsidiary of a foreign corporation (through a merger into the foreign corporation’s U.S. subsidiary) or transfers its assets to the foreign corporation, but at the same time keeps most of its operations in the United States. Inversions are especially popular these days for pharmaceutical and biotechnology companies, where most of the value of the company is found in intangible assets.

The Internal Revenue Code provides two primary incentives for these types of transactions: (1) U.S. corporations are subject to federal income tax on their worldwide income, and (2) U.S. corporations are able to defer from U.S. federal income tax certain categories of income from foreign operations until the income is repatriated to the United States in the form of a dividend.

While an inversion transaction is typically a taxable transaction under Section 367(a), if the transaction is otherwise respected, U.S. federal income tax can be deferred on foreign operation until repatriated, and there are opportunities to reduce the taxable income of the U.S. operations by making deductible payments of interest, royalties and other fees to the foreign parent.

Under Section 7874, a foreign corporation is treated as a U.S. corporation for all purposes of the Code where, under a plan or series of related transactions:

1. The foreign corporation completes, after March 4, 2003, the direct or indirect acquisition of substantially all the properties held directly or indirectly by a U.S. corporation;

2. Shareholders of the U.S. corporation obtain 80% or more of the foreign corporation’s stock (by vote or value) by reason of holding their U.S. shares; and

3. The foreign corporation and corporations connected to it by a 50% chain of ownership (the “expanded affiliated group”) does not have substantial business activities in the foreign corporation’s country of incorporation or organization when compared to the total business activities of the group. For this purpose, substantial business activities requires the expanded affiliated group to have at least 25 percent of (i) the group employees; (ii) group assets; and (iii) group income in the foreign country of incorporation.

The same rule applies where a domestic partnership transfers substantially all the properties of a trade or business to a foreign corporation and the same stock ownership and absence of business activities tests are met.

Where, however, the inversion transaction satisfies the above three tests, except that the domestic corporation’s shareholders (or a domestic partnership’s partners) obtain at least 60% but less than 80% of the foreign corporation’s stock, the foreign corporation is a “surrogate foreign corporation” respected as a foreign corporation. The inversion gain recognized by the “expatriated entity,” however, is taxable in full with no reduction or offset for losses, credits or other tax attributes. Also, for ten years after the expatriation transaction is completed, the expatriated entity’s gain on transfers or licenses to the surrogate foreign corporation or to a “foreign related person” is taxable without offset (with an exception for inventory and like property).

2012 Regulations Aimed at Discouraging Inversions were Ineffective  

Historically, most inversion transactions were merely internal restructurings where the new foreign parent had little substance in its country of incorporation. In 2012, however, final regulations were issued that moved away from a “facts and circumstances” business activities test and introduced the new 25 percent safe harbor tests discussed above. It was assumed that these changes would make it much more difficult for inverted companies to satisfy the business activities test and therefore discourage U.S. companies from inverting.

What has happened, however, is that U.S. companies have resorted to simply acquiring smaller foreign companies (typically at large premiums, in effect paying for the future tax savings) to satisfy the business activities test. (For example, last May, New Jersey based Actavis PLC agreed to acquire Ireland’s Warner Chilcott at a 34% premium over its then existing stock price). Most of these companies have been located in low-tax jurisdictions such as Ireland, which has a 12.5 percent corporate income tax rate, or, in the case of the failed Pfizer-Astra Zeneca deal, the U.K., which has favorable regime for the taxation of income derived from patents.

Further Legislation Likely to be Part of Overall Tax Reform

Shortly after new proposed legislation was introduced a few weeks ago that was designed to shut down inversion transactions completely, U.S. medical device maker Medtronic announced that it is taking over competitor Covidien and moving its tax residence to Ireland. Although this deal bears many similarities to the failed Pfizer takeover attempt of Astra Zeneca last month, Medtronic’s main tax motivation supposedly is to gain access to cash trapped overseas. According to a Covidien press release, the combined company will have its principal executive offices in Ireland, “where both companies have a longstanding presence.” Medtronic will, however, continue to have its operational headquarters in Minneapolis.

The timing of the Medtronic announcement seems to indicate that U.S. companies do not believe that further legislation will be enacted any time soon. In fact, it is generally believed that Congress is of the view that corporate inversions are a symptom of a broken, uncompetitive tax system, and that the system should be reformed so that the United States is a more attractive place to do business.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Bilzin Sumberg | Attorney Advertising

Written by:

Bilzin Sumberg

Bilzin Sumberg on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.